# **Special Issue**

### COVID-19 Vaccination: Considerations for Public Health and Policy

#### Message from the Guest Editors

Development and large-scale implementation of COVID-19 vaccination represent a promising tool for reaching herd immunity and ending this global crisis. In this Special Issue, original research articles and different types of evidence-summaries are welcome. Research areas may include (but not limited to) the following:

- COVID-19 vaccine acceptance, hesitancy, and refusal, including assessments of the evolving epidemiology and understating of individual, group –level and context-specific determinants of these phenomena.
- Monitoring and continued development of COVID-19 vaccines, including efficacy and effectiveness of vaccines in the context of emerging variants, safety, booster doses, mixing and matching vaccines.
- Public health and policy issues, including vaccine deployment, ensuring equitable access, communication strategies for encouraging vaccine uptake and introduction of vaccine passports.

We look forward to receiving your contributions. Drs. Stojanovic and Lavoie

#### **Guest Editors**

Dr. Jovana Stojanovic

Prof. Dr. Kim L. Lavoie

Prof. Dr. Simon Bacon

Deadline for manuscript submissions closed (31 August 2022)



an Open Access Journal by MDPI

Impact Factor 5.2 CiteScore 8.9 Indexed in PubMed



mdpi.com/si/92528

Vaccines MDPI, Grosspeteranlage 5 4052 Basel, Switzerland Tel: +41 61 683 77 34 vaccines@mdpi.com

mdpi.com/journal/

vaccines





an Open Access Journal by MDPI

Impact Factor 5.2 CiteScore 8.9 Indexed in PubMed



vaccines



## About the Journal

#### Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

#### Editor-in-Chief

Prof. Dr. Ralph A. Tripp Department of Infectious Diseases, College of Veterinary Medicine, University of Georgia, Athens, GA 30602-7387, USA

#### **Author Benefits**

#### **High Visibility:**

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Immunology) / CiteScore - Q1 (Pharmacology (medical))

#### **Rapid Publication:**

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.6 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the second half of 2024).